Report overview
This report contains market size and forecasts of Hematological Malignancy Drugs in Global, including the following market information:
Global Hematological Malignancy Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hematological Malignancy Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monoclonal Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hematological Malignancy Drugs include Roche, Celgene, Novartis, Bristol-Myers Squibb, Johnson & Johnson, Merck & Co., AstraZeneca, Pfizer and Amgen, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hematological Malignancy Drugs companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hematological Malignancy Drugs Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hematological Malignancy Drugs Market Segment Percentages, by Type, 2021 (%)
Monoclonal Antibody
Immunomodulatory Drug
Tyrosine Kinase Inhibitor
Proteasome Inhibitors
Others
Global Hematological Malignancy Drugs Market, by Indication, 2017-2022, 2023-2028 ($ millions)
Global Hematological Malignancy Drugs Market Segment Percentages, by Indication, 2021 (%)
ALL
CLL
AML
NHL
DLBCL
MM
Others
Global Hematological Malignancy Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hematological Malignancy Drugs Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hematological Malignancy Drugs revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hematological Malignancy Drugs revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Celgene
Novartis
Bristol-Myers Squibb
Johnson & Johnson
Merck & Co.
AstraZeneca
Pfizer
Amgen
Eli Lilly
AbbVie
Takeda
Sanofi
Bayer
Biogen Idec
